Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib in Refractory cGVHD
NCT07012304Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in chronic graft-versus-host disease (cGVHD). Started Jun 2025; status: recruiting.
02
Drugs
jaktinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07012304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012304.